Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...

Key market opportunities for Cas12 proteins include rising government investments in biotech, increased demand for ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Colossal Biosciences expands its de-extinction mission by acquiring Viagen, the world leader in animal cloning and species ...

While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Although heart cells and skin cells contain identical instructions for creating proteins encoded in their DNA, they're able ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...